1 of 1
Story summary
- The U.S. Food and Drug Administration announced a nationwide recall of compounded tirzepatide injections.
- Apothecary Pharma LLC voluntarily recalled 22 vials on Sept. 24.
- The FDA reclassified the recall as Class II on Oct. 10, indicating reversible health risks.
- Recall lot codes AP-202622 through AP-202644 have beyond-use dates from Oct. 7 to Nov. 26, 2026.
- The agency warned patients not to use compounded GLP-1s unless brand-name drugs cannot meet needs.